Introduction {#Sec1}
============

Safe and effective vaccines against hepatitis B (HB) infection have been available since 1982. The World Health Organization (WHO) recommends universal vaccination against HB to ultimately eliminate HB; this recommendation had been progressively implemented, with 168 countries having with a universal immunization program by the end of 2006 \[[@CR1]\].

Neonatal vaccines have certain medical advantages, namely, they produce early protection for the vulnerable newborn period, and there is the advantage of birth cohort accessibility. However, newborns do have impaired immune responses due to a range of deficiencies in both adaptive immunity and innate immunity as well as the potentially suppressive effects of maternally derived antibodies \[[@CR2]\].

The duration of protection after HB vaccination of infants vaccinated at birth is unknown, although more recent studies have found that after neonatal immunization with HB vaccine, a large proportion of the children, especially adolescents, exhibited waning immunity. Such decreased protection poses the risk of breakthrough infection \[[@CR3]--[@CR5]\]. It is generally assumed that the long-term efficacy of HB vaccine depends primarily on peak antibody levels after vaccination. The study of McMahon et al. \[[@CR6]\] revealed that children vaccinated in early childhood were more likely to have undetectable levels of hepatitis B surface antibody (anti-HBs) in late adolescence or young adulthood, when the risks for HB infection increase. Other studies have shown that lower seroconversion rates occurred in children after primary vaccination if they had received the vaccine immediately after birth \[[@CR7]--[@CR9]\].

Universal HB immunization began in 1998 in Turkey \[[@CR10]\]. Children born to seronegative mothers were vaccinated according to the 2--4--9 (age in months) schedule between 1998 and 2002; thereafter, the vaccination schedule was changed to 0--2--9 months and remained so until 2007. Since 2008, the 0--1--6 vaccination scheme has been applied \[[@CR11]\]. The aim of this study was to compare the immunogenicity of HB vaccine administered in the two different vaccination schemes starting either at month 2 of life or at birth.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

This descriptive cross-sectional study was performed at the Gazi University Faculty of Medicine Well-Child Clinic between June 2004 and June 2005. The study cohort consisted of all infants who made routine well-child visits to the clinic, whose parents gave informed consent for the study, and who fulfilled the following inclusion criteria: (1) age between 18 and 30 months; (2) made regular visits to the clinic for routine check-ups; (2) were born to hepatitis B surface antigen (HBsAg)-negative mothers; (4) showed no sign of chronic disease; (5) gestational age was \>37 weeks and birth weight was \>2,000 g; (6) primary hepatitis B vaccination program was completed in this clinic according to either the 0--2--9 or 2--4--9 schedule.

A total of 267 infants satisfied all inclusion criteria and were enrolled in the study. Of these, 111 infants received three doses of vaccine at months 0, 2, 9 (group 1) and 156 infants received three doses of vaccine at months 2, 4, 9 (group 2). Vaccines for diphtheria, pertussis, tetanus, and live polio were concomitantly given at the second and fourth months. Age and anti-HBs values of the mothers and gestational age, birth weight, and gender of the child were recorded on the well-child visit chart.

Ethical aspects {#Sec4}
---------------

The study protocol was approved by the ethical committee of Gazi University Medical Faculty.

Vaccines {#Sec5}
--------

All infants were administered 0.5 ml (10 μg) of Euvax B vaccine, which is provided in the form of 10-ml glass vials (LG Life Sciences, Iksan-si, Korea). The vaccine contains 10 mg purified HBsAg (*Saccharomyces cerevisiae* is produced by recombinant DNA technology in yeast cells), 0.25 mg aluminum hydroxide gel, and 0.01% (w/v) thiomersal. The vaccines were always stored at 2--8°C and given intramuscularly in the anterolateral thigh according to either of one of the vaccination schedules.

Laboratory methods {#Sec6}
------------------

Hepatitis B surface antigen, anti-HBs, and hepatitis B core antibody (anti-HBc) were measured by enzyme-linked immunosorbent assays (ELISA) using commercial test kits (UniCel DxI 800 System; Beckman Coulter, CA) in accordance with the manufacturer's instructions. Anti-HBs is expressed in international units per liter (IU/L) after comparison with the WHO reference standard. The lower limit of detection for the ELISA was 5 IU/L. Serum samples were studied on the same day. All children with an anti-HBs concentration ≥10 IU/L were considered to be seroprotected.

Statistical methods {#Sec7}
-------------------

Statistical analysis was performed using SPSS ver. 15.0 software (SPSS, Chicago, IL). Descriptive values for continuous variables were given as the mean ± standard deviation (SD), while categoric variables were expressed as number and percentage. All data were tested for normal distribution, and comparisons were made with parametric and nonparametric tests for normally distributed and non-normally distributed variables, respectively. The Spearman correlation test was performed for the correlation analysis.

Anti-HBs concentrations were log-transformed prior to calculating the geometric mean titer (GMT). For analytic purposes, children with undetectable anti-HBs were assigned a value of 2.5 IU/L. A *t* test was used to compare the log-transformed peak anti-HBs concentrations, while proportions were compared using a chi-square tests. A *p* value \<0.05 was considered to be statistically significant.

Results {#Sec8}
=======

All 267 infants who participated in the study showed no evidence of HB infection. The mean age of the children was 23.22 ± 2.36 months (minimum 18, maximum 30, median 24 months). Duration after primary immunization and blood sampling for both groups was 14.22 ± 2.36 months (minimum 9, maximum 21, median 15 months). The quantitative anti-HBs value for 12 mothers (1 in group 1, 11 in group 2) could not be obtained because they were measured in another laboratory; these mothers were therefore excluded from the study. There were no significant differences between the two groups in terms of the age or the anti-HBs GMT levels of the mothers, gestational age, mean interval between the last dose of HB vaccine and blood sampling, and birth weight or gender of the infants (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of study groupsGroup 1^a^ (*n* = 111)Group 2^b^ (*n* = 156)Total (*n* = 267)*p*Children Mean age (months)23.12 ± 2.6123.29 ± 2.1723.22 ± 2.360.540 Gender (*n*)  Male60751350.336  Female5181132 Gestational age (weeks)38.68 ± 1.0738.71 ± 1.1638.7 ± 1.120.813 Birth weight (g)3,248 ± 384.53,340 ± 433.33,301 ± 415.40.075 Mother's age (years)29.01 ± 4.629.66 ± 4.529.39 ± 4.570.259 Anti-HBs GMT (IU/L)95.00379.510.0001 Positive anti-HBs (%)^c^90.199.40.0001Group 1^a^ (*n* = 110)Group 2^b^ (*n* = 145)Total (*n* = 255)*p*Mothers Prenatal Anti-HBs GMT of mothers (IU/L)6.3495.1400.297 Prenatal Anti-HBs titer ≥ 10 IU/L of mothers (%)25.2250.357GMT, Geometric mean titer; anti-HbBs, hepatitis B surface antibodyWhere appropriate, data are given as the mean ± standard deviation (SD)^a^Group 1, infants who received three doses of hepitatis B (HB) vaccine at months 0, 2, 9 of life^b^Group 2, infants who received three doses of HB vaccine at months 2, 4, 9 of life^c^Anti-HBs \>10 IU/L

There was no correlation between the anti-HBs levels of mothers and infants (*p* = 0.850).

Anti-HBs GMT levels of infants in group 1 and 2 were 95.00 and 379.51 IU/L respectively (*p* = 0.0001).

Figure [1](#Fig1){ref-type="fig"} shows the frequencies of protective levels of anti-HBs after primary vaccination in the two different vaccination schemes. Anti-HBs levels ≥10 IU/L after primary vaccination in infants who received the first vaccination at month 2 (group 2) and at birth (group 1) were 99.4 and 90.1%, respectively (Fisher's Exact test *p* = 0.0001).Fig. 1Immunological responses in two different Hepatitis B vaccination schedules

In terms of long-term protection, anti-HBs levels ≥100 IU/L were considered to be important. In infants whose first dose of HB vaccination was received at 2 months of age, 94.9% had anti-HBs levels ≥100 IU/L after the primary vaccination, while in infants whose vaccination started at birth, this was only 57.7% (Fisher's Exact test *p* = 0.0001). When factors associated with long-term protection were analyzed, prenatal anti-HBs level of the mother (*p* = 0.197), gestational age (≤37 weeks) (*p* = 0.576), and gender (*p* = 0.305) were statistically insignificant. Antibody titers ≥100 IU/L were 13.59-fold higher in the infants of group 2 than in those of group 1 (odds ratio 13.59, 95% confidence interval 5.77--33.14; *p* = 0.0001).

Discussion {#Sec9}
==========

Members of the medical profession consider an anti-HBs level ≥10 IU/L to be protective against HB infection \[[@CR12]\]; in addition, an anti-HBs level ≥100 IU/L is taken as evidence of long-lasting immunity \[[@CR13]\]. The duration of immunity after HB vaccination is currently unknown, but it is generally assumed that the higher the antibody levels after vaccination, the longer the period of protection \[[@CR13]--[@CR15]\]. Our study shows that although the vaccine was highly immunogenic in both of the vaccination schemes investigated, the scheme starting at the end of second month of life yielded a significantly higher immunogenicity than that starting at birth. Only limited data are currently available to compare alternate schedules against the conventional schedule, but our results do confirm those from a number of previous studies \[[@CR7], [@CR8], [@CR16]\]. The subjects in these three studies were all infants of HBsAg-negative mothers, and the results showed that these infants had lesser seroconversion if they received the first dose of HB vaccine immediately after delivery instead of 2 months after birth. In another study on the protective effects of HB vaccine in infants of HBsAg-positive mothers who were followed up for 36 months, HB infections were observed to be more frequent in infants whose vaccination started at birth \[[@CR17]\], likely due to the insufficient maturation of the immune system in newborn infants. Furthermore, maternally derived antibodies can interfere with active immunization. Weeratna et al. \[[@CR18]\] showed that B cell responses remained weak when newborn mice were immunized against HBsAg in the presence of high levels of maternal antibody against HBsAg, and Hu et al. \[[@CR19]\] showed that passively acquired maternal anti-HBs in infants may, to some extent, impair the antibody response to HB vaccine. In our study, there were no differences between the anti-HBs levels of mothers of the two groups in pregnancy, whereas infants showed lower seroconversion if they received the first dose of HB vaccine immediately after delivery. We consider the immunological immaturity of the newborn to be the predicting factor of antibody levels in the postvaccination period.

A number of studies have shown that persistence of HBs antibodies is not long term in babies who are vaccinated at birth. In two studies of children 5--6 years after they had received the primary vaccination with recombinant HB vaccine, Petersen et al. \[[@CR20]\] found that 12.5% and Seto et al. \[[@CR21]\] found that 19% of the children had protective levels of anti-HBs antibodies. In comparison, West et al. \[[@CR22]\] found that the anti-HBs titer was ≥10 after 12 years in all of the children vaccinated with plasma-derived HB vaccine 2--3 months after birth.

Stevens et al. \[[@CR9]\] showed that the immune response was enhanced by delaying the initial injection to 1 month after birth and the third injection to 6--9 months of age. A number of authors reported that in their studies the concentrations of anti-HBs after the third injection were dependent on the interval between the second and the third dose. Children receiving the third vaccine dose relatively late developed antibody titers higher than those receiving the third dose on schedule \[[@CR13], [@CR14], [@CR23]\]. In our study, the interval between the second and third doses for those infants vaccinated at birth was longer than that for infants vaccinated at the second month, but we did not observe any positive impact of this difference on antibody levels.

At the present time, there are no assays to measure correlates of protection against HB infection directly \[[@CR24]\]. It is therefore possible that immunological memory itself depends on the development of a protective level of antibodies after vaccination. However, there is a strong belief that a high proportion of children vaccinated in early childhood retain immune memory and develop an anti-HBs response upon exposure to HB later in life. Thus, even if anti-HBs concentrations decline to \<10 IU/L, immune memory would continue to persist over a longer time \[[@CR1], [@CR25]\]. It is likely that vaccinated children born to HBsAg-positive mothers or living in areas where HB infection is endemic are exposed to HB throughout childhood. Such children can obtain natural booster doses. However, the duration of immunity among children born to HBsAg-negative mothers or those living in low endemicity settings may be shorter due to the absence of natural boosting. Turkey is known to have moderate HB endemicity \[[@CR26]\]; thus children born to HBsAg-negative mothers need long-term protectivity. If immunological memory may later decline or become undetectable, the risk of breakthrough infection may occur. Some countries have chosen not to implement immunization at birth and instead screen pregnant women for HBsAg \[[@CR27]\]. The HB vaccine birth dose is then given only to infants born to HBsAg-positive mothers. In our country, the initial vaccination for infants born to HBsAg-negative mothers (in many metropolises HB markers can be screened) may be delayed until a few months after birth, the first vaccination time of other routine infant vaccine antigens (DaPT--IPV--Hib and conjugated pneumococcus). This vaccination can be easily performed in combination with other vaccines, thus reducing the number of required injections, simplifying administration and improving immunization rates. Screening also enables medical professionals to identify HB carriers, thereby providing an opportunity to give HB immunoglobulin to infants born to these mothers. However, screening is costly and not usually feasible in developing countries. In countries where screening programs for pregnancy are not available, vaccination at birth for HB perinatal infections is still a necessity. However, such infants should be followed up to evaluate whether or not they will have long-term immunity. Our study is a preliminary report, and we plan to follow up these infants until puberty and evaluate their immunological status.
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